Vikas Londhe on Andexxa’s Safety Assessment Updates
Vikas Londhe, Chief Editor of Pharmacally.com, shared on LinkedIn:
”FDA Safety Update: Andexxa Risks Outweigh Benefits After Postmarketing Thromboembolic Events—Market Withdrawal Planned
FDA Updates Safety Assessment of Andexxa After Serious Thromboembolic Events.
On December 18, 2025, the U.S. Food and Drug Administration (FDA) issued a safety communication regarding Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo).
The agency has reviewed postmarketing safety data showing an increased incidence of thromboembolic events, including serious and fatal outcomes, in patients treated with Andexxa.
Based on these findings, the FDA now considers that the risks associated with Andexxa outweigh its benefits in its approved use.”
Read the full announcement here.
Stay updated with Hemostasis Today.
-
Jul 14, 2026, 19:35Daratumumab in Difficult-to-Treat iTTP: Updated Results from the International DarTTP Study
-
Jul 14, 2026, 17:1610 Posts Not To Miss from ISTH 2026, Part 3
-
Jul 14, 2026, 15:27Dianne E Van Der Wal: Celebrating Scientific Contributions at ISTH 2026
-
Jul 14, 2026, 15:13Alfonso Tafur: RIETE Registry Analysis Supports More Equitable Approaches to VTE Care
-
Jul 14, 2026, 15:03Heghine Khachatryan: Phase III Trial Results Support BAFF-R Inhibition in Corticosteroid-Refractory ITP
-
Jul 14, 2026, 14:51Nathan Connell: ISTH 2026 Highlights the Power of Lifelong Collaboration
-
Jul 14, 2026, 14:42Wolfgang Miesbach: VOYAGER1 Highlights Progress Toward Injection-Free Care in Hemophilia A
-
Jul 14, 2026, 12:08Elvira Grandone: Finding the Right LMWH Dose for Pregnant Patients Suffering From DVT
-
Jul 14, 2026, 12:05Eloïse Laouenan: From Washington to Paris – Join GETBO at ISTH 2026